This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
A federal judge rejected LegitScript’s motion to dismiss the case, which alleges efforts to hide low-cost prescription options from consumers.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Te new board will address high prescription drug prices that are unaffordable to many and make up a large portion of state health spending.
As insulin-makers face long-standing complaints of price-gouging, California is diving into the prescription drug business, attempting to produce its own brand of generic insulin and sell it at below-market prices to people with diabetes.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state’s Prescription Price Transparency Program received reports of nearly 200 new high-cost drugs this past year.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The Lund Report asked the Congressman about what makes his plan different from the proposal he recently voted against.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The civil lawsuit, alleging anti-competitive practices by Portland firm LegitScript, may move to Oregon venue.
A Pfizer win in a lawsuit against the federal government could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts.
The bill would tie U.S. drug prices to a median price in 11 countries where prescriptions are much cheaper.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
But they face drug industry opposition as they consider bills to make generic drugs more available, limit out-of-pocket insulin costs and set price limits on expensive drugs.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state released its latest drug transparency data, which shows that Humira, used for rheumatoid arthritis, racked up $81 million in sales over the past year.
